Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint

To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ). 70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st ( =3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Terapevtic̆eskii arhiv 2023-12, Vol.95 (12), p.1141
Hauptverfasser: Mazurov, V I, Belyaeva, I B, Trofimov, E A, Itskovich, I E, Burulev, A L
Format: Artikel
Sprache:rus
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 12
container_start_page 1141
container_title Terapevtic̆eskii arhiv
container_volume 95
creator Mazurov, V I
Belyaeva, I B
Trofimov, E A
Itskovich, I E
Burulev, A L
description To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ). 70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st ( =35) took AN 1 caps/day, in the 2nd ( =35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators. Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups. The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_38785054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38785054</sourcerecordid><originalsourceid>FETCH-pubmed_primary_387850543</originalsourceid><addsrcrecordid>eNqFkE1OAzEMRgeJilbQKyAfoJVSTf_WFBDds6_cxNNJSZxR4ima25NUZcWClfXZT8-y76uJUks1r9drNa6mKZ2VUovlar3YbB6qcb3dbFdqtZzcjXbBdxhR7IWAmsZq1AOEBhB08EfLeRK4NHo2lFMfyYAMHcF-nxHn8EQ8g5eQvsk5qwG1NWkGnqQdXOpdE3hwJSHTDC5W0FtOsANkA69QX-ufbboNbGKwYhmKBIWu4Mn1OqSiIGiHTOjWhWgNQQalJZBIKJ5YiqWL1mPM9yShgFHamIWpTAr6xURwDpblqRo16BJNb_Wxen5_-9x9zLv-6Mkcbp7D79_qf4EfD45_1g</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><creator>Mazurov, V I ; Belyaeva, I B ; Trofimov, E A ; Itskovich, I E ; Burulev, A L</creator><creatorcontrib>Mazurov, V I ; Belyaeva, I B ; Trofimov, E A ; Itskovich, I E ; Burulev, A L</creatorcontrib><description>To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ). 70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st ( =35) took AN 1 caps/day, in the 2nd ( =35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators. Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups. The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.</description><identifier>ISSN: 0040-3660</identifier><identifier>PMID: 38785054</identifier><language>rus</language><publisher>Russia (Federation)</publisher><subject><![CDATA[Aged ; Ascorbic Acid - administration & dosage ; Ascorbic Acid - pharmacology ; Chondroitin Sulfates - administration & dosage ; Chondroitin Sulfates - pharmacology ; Collagen Type II - administration & dosage ; Dimethyl Sulfoxide - administration & dosage ; Dimethyl Sulfoxide - pharmacology ; Drug Therapy, Combination ; Female ; Glucosamine - administration & dosage ; Glucosamine - pharmacology ; Humans ; Male ; Middle Aged ; Osteoarthritis, Knee - drug therapy ; Pain Measurement ; Quality of Life ; Severity of Illness Index ; Sulfones - administration & dosage ; Sulfones - pharmacology ; Treatment Outcome ; Triterpenes - administration & dosage ; Triterpenes - pharmacology]]></subject><ispartof>Terapevtic̆eskii arhiv, 2023-12, Vol.95 (12), p.1141</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-8352-3955 ; 0009-0007-5401-5047 ; 0000-0002-0797-2051 ; 0000-0003-3236-4485 ; 0000-0002-7981-6349</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38785054$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazurov, V I</creatorcontrib><creatorcontrib>Belyaeva, I B</creatorcontrib><creatorcontrib>Trofimov, E A</creatorcontrib><creatorcontrib>Itskovich, I E</creatorcontrib><creatorcontrib>Burulev, A L</creatorcontrib><title>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</title><title>Terapevtic̆eskii arhiv</title><addtitle>Ter Arkh</addtitle><description>To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ). 70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st ( =35) took AN 1 caps/day, in the 2nd ( =35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators. Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups. The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.</description><subject>Aged</subject><subject>Ascorbic Acid - administration &amp; dosage</subject><subject>Ascorbic Acid - pharmacology</subject><subject>Chondroitin Sulfates - administration &amp; dosage</subject><subject>Chondroitin Sulfates - pharmacology</subject><subject>Collagen Type II - administration &amp; dosage</subject><subject>Dimethyl Sulfoxide - administration &amp; dosage</subject><subject>Dimethyl Sulfoxide - pharmacology</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Glucosamine - administration &amp; dosage</subject><subject>Glucosamine - pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteoarthritis, Knee - drug therapy</subject><subject>Pain Measurement</subject><subject>Quality of Life</subject><subject>Severity of Illness Index</subject><subject>Sulfones - administration &amp; dosage</subject><subject>Sulfones - pharmacology</subject><subject>Treatment Outcome</subject><subject>Triterpenes - administration &amp; dosage</subject><subject>Triterpenes - pharmacology</subject><issn>0040-3660</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1OAzEMRgeJilbQKyAfoJVSTf_WFBDds6_cxNNJSZxR4ima25NUZcWClfXZT8-y76uJUks1r9drNa6mKZ2VUovlar3YbB6qcb3dbFdqtZzcjXbBdxhR7IWAmsZq1AOEBhB08EfLeRK4NHo2lFMfyYAMHcF-nxHn8EQ8g5eQvsk5qwG1NWkGnqQdXOpdE3hwJSHTDC5W0FtOsANkA69QX-ufbboNbGKwYhmKBIWu4Mn1OqSiIGiHTOjWhWgNQQalJZBIKJ5YiqWL1mPM9yShgFHamIWpTAr6xURwDpblqRo16BJNb_Wxen5_-9x9zLv-6Mkcbp7D79_qf4EfD45_1g</recordid><startdate>20231228</startdate><enddate>20231228</enddate><creator>Mazurov, V I</creator><creator>Belyaeva, I B</creator><creator>Trofimov, E A</creator><creator>Itskovich, I E</creator><creator>Burulev, A L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><orcidid>https://orcid.org/0000-0001-8352-3955</orcidid><orcidid>https://orcid.org/0009-0007-5401-5047</orcidid><orcidid>https://orcid.org/0000-0002-0797-2051</orcidid><orcidid>https://orcid.org/0000-0003-3236-4485</orcidid><orcidid>https://orcid.org/0000-0002-7981-6349</orcidid></search><sort><creationdate>20231228</creationdate><title>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</title><author>Mazurov, V I ; Belyaeva, I B ; Trofimov, E A ; Itskovich, I E ; Burulev, A L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_387850543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>rus</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Ascorbic Acid - administration &amp; dosage</topic><topic>Ascorbic Acid - pharmacology</topic><topic>Chondroitin Sulfates - administration &amp; dosage</topic><topic>Chondroitin Sulfates - pharmacology</topic><topic>Collagen Type II - administration &amp; dosage</topic><topic>Dimethyl Sulfoxide - administration &amp; dosage</topic><topic>Dimethyl Sulfoxide - pharmacology</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Glucosamine - administration &amp; dosage</topic><topic>Glucosamine - pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteoarthritis, Knee - drug therapy</topic><topic>Pain Measurement</topic><topic>Quality of Life</topic><topic>Severity of Illness Index</topic><topic>Sulfones - administration &amp; dosage</topic><topic>Sulfones - pharmacology</topic><topic>Treatment Outcome</topic><topic>Triterpenes - administration &amp; dosage</topic><topic>Triterpenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazurov, V I</creatorcontrib><creatorcontrib>Belyaeva, I B</creatorcontrib><creatorcontrib>Trofimov, E A</creatorcontrib><creatorcontrib>Itskovich, I E</creatorcontrib><creatorcontrib>Burulev, A L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Terapevtic̆eskii arhiv</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazurov, V I</au><au>Belyaeva, I B</au><au>Trofimov, E A</au><au>Itskovich, I E</au><au>Burulev, A L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</atitle><jtitle>Terapevtic̆eskii arhiv</jtitle><addtitle>Ter Arkh</addtitle><date>2023-12-28</date><risdate>2023</risdate><volume>95</volume><issue>12</issue><spage>1141</spage><pages>1141-</pages><issn>0040-3660</issn><abstract>To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ). 70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st ( =35) took AN 1 caps/day, in the 2nd ( =35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators. Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups. The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.</abstract><cop>Russia (Federation)</cop><pmid>38785054</pmid><orcidid>https://orcid.org/0000-0001-8352-3955</orcidid><orcidid>https://orcid.org/0009-0007-5401-5047</orcidid><orcidid>https://orcid.org/0000-0002-0797-2051</orcidid><orcidid>https://orcid.org/0000-0003-3236-4485</orcidid><orcidid>https://orcid.org/0000-0002-7981-6349</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0040-3660
ispartof Terapevtic̆eskii arhiv, 2023-12, Vol.95 (12), p.1141
issn 0040-3660
language rus
recordid cdi_pubmed_primary_38785054
source MEDLINE; DOAJ Directory of Open Access Journals
subjects Aged
Ascorbic Acid - administration & dosage
Ascorbic Acid - pharmacology
Chondroitin Sulfates - administration & dosage
Chondroitin Sulfates - pharmacology
Collagen Type II - administration & dosage
Dimethyl Sulfoxide - administration & dosage
Dimethyl Sulfoxide - pharmacology
Drug Therapy, Combination
Female
Glucosamine - administration & dosage
Glucosamine - pharmacology
Humans
Male
Middle Aged
Osteoarthritis, Knee - drug therapy
Pain Measurement
Quality of Life
Severity of Illness Index
Sulfones - administration & dosage
Sulfones - pharmacology
Treatment Outcome
Triterpenes - administration & dosage
Triterpenes - pharmacology
title Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T02%3A32%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20efficacy%20of%20a%20combination%20of%20undenatured%20type%20II%20collagen,%20Boswellic%20acids,%20methylsulfonylmethane,%20vitamins%20C%20and%20D%203%20and%20a%20combination%20of%20chondroitin%20sulfate%20and%20glucosamine%20hydrochloride%20in%20the%20treatment%20of%20primary%20osteoarthritis%20of%20the%20knee%20joint&rft.jtitle=Terapevtic%CC%86eskii%20arhiv&rft.au=Mazurov,%20V%20I&rft.date=2023-12-28&rft.volume=95&rft.issue=12&rft.spage=1141&rft.pages=1141-&rft.issn=0040-3660&rft_id=info:doi/&rft_dat=%3Cpubmed%3E38785054%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38785054&rfr_iscdi=true